Androgen therapy is the mainstay of treatment in female to male (FtM) transgender persons to increase testosterone levels, suppress oestrogens and treat gender dysphoria. Testosterone is widely used for male hypogonadism, but is comparatively under-investigated in FtM transgender persons. The aim of our study was to identify treatment and safety outcomes associated with testosterone use in transgender medicine. Androgens in FtM transgender persons are effective to lower voice frequency, increase facial hair-growth, and increase hematocrit and hemoglobin levels to adult male reference ranges. A 1.2-fold-3.7-fold higher rate of myocardial infarction has been reported retrospectively, compared to cisgender women. Blood pressure, glycaemic control and body mass index remained unchanged in FtM transgender persons. Androgens in FtM transgender persons have important cardio-metabolic implications. Randomised control trials, longer follow-up periods and studies involving older persons may further improve the management of FtM transgender persons.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beem.2022.101617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reproductive functions and fertility preservation in transgender men: A French case series.
J Gynecol Obstet Hum Reprod
December 2024
Service de Biologie de la Reproduction CECOS, Hôpital Tenon (AP-HP), Sorbonne-Université 75020 PARIS, France; Sorbonne Université, Centre de recherche Saint-Antoine, Inserm US938 75012 PARIS, France. Electronic address:
Background: Transgender men face reproductive challenges due to the potential impact on fertility of gender-affirming hormone therapy (GAHT) and surgical interventions. Testosterone therapy during "female to male" transition leads to anovulation and amenorrhea. Although these effects are typically reversible upon stopping treatment, the long-term effects of androgens on future fertility and health of potential children remain poorly known.
View Article and Find Full Text PDFAssociations between Androgen Exposure, Polycystic Ovary Syndrome, and Transmasculine Individuals with Central Serous Chorioretinopathy.
Ophthalmol Retina
November 2024
Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Cole Eye Institute, Cleveland, Ohio. Electronic address:
Purpose: The prevalence of central serous chorioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed patients remains largely unexplored. Although these groups involve patients with elevated testosterone levels, previous literature is inconclusive on the influence of testosterone on CSCR. This study aimed to determine the relationship between CSCR and cohorts with exogenous androgen exposure, female-to-male (FTM) transgender individuals, and those diagnosed with PCOS.
View Article and Find Full Text PDFAndrogen receptor expression in recurrent granulosa cell tumor of the ovary: Clinical considerations of treatment and surveillance in a transgender male.
Gynecol Oncol Rep
December 2024
Department of Gynecologic Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States.
Granulosa cell tumors (GCT) represent a rare subtype of ovarian cancers. A majority of these tumors express androgen receptor (AR), making them hormonally sensitive. AR positivity not only suggests a potential role of anti-androgen therapy in treating these tumors but also poses a cause for concern: female to male (FTM) transgender patients undergoing exogenous testosterone therapy may be at risk for recurrence, progression, or even incidence of this type of cancer.
View Article and Find Full Text PDFThe gender of PrEP: Transgender men negotiating legitimacy in France.
Soc Sci Med
May 2024
Université d'Aix-Marseille, Ideas, 5 rue du Château de l'Horloge, 13090, Aix-en-Provence, France. Electronic address:
Transmasculine people (TM) constitute an invisibilized group within the transgender population. Little is known about their relationship to sexuality in transgender medicine. Their presence and needs are still unacknowledged within HIV prevention research and services.
View Article and Find Full Text PDFFertility preservation choices and decisional regret after gender-affirming surgery in transgender men or gender nonbinary persons.
F S Rep
March 2024
Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Objective: To investigate the prevalence of decisional regret regarding preoperative fertility preservation choices after gender-affirming surgery or removal of reproductive organs.
Design: Cross-sectional.
Setting: University-based pratice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!